You are here
The objective of the IHPA Impact of New Health Technology Framework (the Framework) is to outline the process by which IHPA, through the CAC, will monitor and review the impact of new health technologies on the existing classifications in order to accurately account for them in the pricing of public hospital services.
In consultation with the CAC, IHPA will:
The purpose of the Framework is to guide the timely, equitable and transparent processes by which IHPA investigates both cross-border and cost-shifting disputes following a request by a Health Minister.
A jurisdiction may request IHPA to consider any legitimate and unavoidable costs in the delivery of public hospital services. The purpose of this Framework is to assist jurisdictions in making submissions to IHPA on this issue, to layout the process which IHPA will follow in assessing submissions, and the process to determine adjustments to the NEP.
The Tier 2 Non-Admitted Services Compendium provides guidance on the counting and classification rules associated with the Tier 2 Non-Admitted Services Classification (Tier 2).
The Tier 2 Non-Admitted Services Classification (Tier 2) supports the introduction of activity based funding (ABF) for non-admitted hospital services in the Australian public hospital system.
The Independent Hospital Pricing Authority (Pricing Authority) is established under the National Health Reform Act 2011 (Cth) (the Act), and by virtue of section 131(1) of the Act is invested with the following functions relevant to this 2018-19 National Efficient Cost Determination (Determination):
The Australian Hospital Patient Costing Standards (AHPCS) provide direction for hospital patient costing through the development of standards for specific elements of the costing process and reporting requirements.
The AHPCS Version 4.0 was developed through extensive consultation with jurisdictions and stakeholders. The AHPCS Version 4.0 comprises:
IHPA has developed a robust set of standard costs for the revised List of standard items associated with conducting clinical trials in Australia.
The Independent Hospital Pricing Authority is established under the National Health Reform Act 2011 (Cth) (the Act), and by virtue of section 131(1) of the Act is invested with the following functions relevant to this 2015-16 National Efficient Cost Determination: